| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
232,140,000 |
| Market
Cap: |
1.80(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.23 - $9.74 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ardelyx is a biopharmaceutical company focused on discovering, developing and commercializing medicines. This includes adult patients with irritable bowel syndrome with constipation (IBS-C), adult patients with chronic kidney disease (CKD) on dialysis suffering from elevated serum phosphorus, or hyperphosphatemia; and adult patients with CKD and/or heart failure with elevated serum potassium, or hyperkalemia. Co.'s product pipeline includes among other, IBSRELA, a sodium hydrogen exchanger 3 inhibitor for the treatment of IBS-C in adults; and XPHOZAH, which is a medicine being developed for the control of serum phosphorus in adult patients with CKD on dialysis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
585,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,011,778 |
| Total People Bought |
0 |
0 |
0 |
7 |
| Total Buy Transactions |
0 |
0 |
0 |
7 |
| Total Shares Sold |
766,409 |
1,189,266 |
1,315,394 |
1,951,649 |
| Total Sell Value |
$6,577,948 |
$9,083,370 |
$9,535,666 |
$10,165,404 |
| Total People Sold |
8 |
8 |
8 |
8 |
| Total Sell Transactions |
18 |
37 |
59 |
102 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Williams Laura A |
Chief Medical Officer |
• – – |
2023-02-21 |
4 |
S |
$3.00 |
$9,564 |
D/D |
(3,187) |
319,013 |
|
-15% |
|
| Raab Michael |
President & CEO |
• • – |
2023-02-21 |
4 |
S |
$3.00 |
$40,360 |
D/D |
(13,449) |
896,012 |
|
-15% |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2023-02-21 |
4 |
S |
$3.00 |
$10,320 |
D/D |
(3,439) |
336,606 |
|
-15% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2023-02-21 |
4 |
S |
$3.00 |
$3,343 |
I/I |
(1,114) |
113,096 |
|
-15% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2023-02-21 |
4 |
S |
$3.00 |
$10,185 |
D/D |
(3,394) |
375,600 |
|
-15% |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2023-02-21 |
4 |
S |
$3.00 |
$8,745 |
D/D |
(2,914) |
329,954 |
|
-15% |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2022-11-22 |
4 |
S |
$1.94 |
$2,421 |
D/D |
(1,242) |
254,868 |
|
-150% |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2022-11-22 |
4 |
S |
$1.94 |
$2,931 |
D/D |
(1,504) |
262,045 |
|
-150% |
|
| Williams Laura A |
Chief Medical Officer |
• – – |
2022-11-22 |
4 |
S |
$1.94 |
$2,419 |
D/D |
(1,241) |
244,200 |
|
-150% |
|
| Raab Michael |
President & CEO |
• • – |
2022-11-22 |
4 |
S |
$1.94 |
$12,120 |
D/D |
(6,219) |
659,461 |
|
-150% |
|
| Blanks Robert |
See Remarks |
• – – |
2022-11-22 |
4 |
S |
$1.94 |
$2,853 |
D/D |
(1,464) |
194,363 |
|
-150% |
|
| Rodriguez Susan |
Chief Commercial Officer |
• – – |
2022-11-22 |
4 |
S |
$1.94 |
$6,736 |
D/D |
(3,456) |
282,717 |
|
-150% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2022-11-22 |
4 |
S |
$1.94 |
$943 |
I/I |
(484) |
88,885 |
|
-150% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2022-11-22 |
4 |
S |
$1.94 |
$2,853 |
D/D |
(1,464) |
300,994 |
|
-150% |
|
| Mott David M |
Director |
– • – |
2022-11-17 |
4 |
B |
$1.76 |
$1,000,642 |
D/D |
567,000 |
1,166,765 |
2.39 |
178% |
|
| Blanks Robert |
See Remarks |
• – – |
2022-10-05 |
4 |
AS |
$1.50 |
$150,000 |
D/D |
(100,000) |
195,827 |
|
99% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2022-09-01 |
4 |
S |
$0.92 |
$2,760 |
I/I |
(3,000) |
89,369 |
|
-222% |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2022-08-31 |
4 |
B |
$0.62 |
$1,856 |
D/D |
3,000 |
263,549 |
2.66 |
213% |
|
| Felsch Robert Ora |
See Remarks |
• – – |
2022-08-31 |
4 |
B |
$0.62 |
$1,856 |
D/D |
3,000 |
91,418 |
2.66 |
213% |
|
| Raab Michael |
President & CEO |
• • – |
2022-08-31 |
4 |
B |
$0.62 |
$1,856 |
D/D |
3,000 |
665,680 |
2.73 |
213% |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2022-08-31 |
4 |
B |
$0.62 |
$1,856 |
D/D |
3,000 |
256,110 |
2.66 |
213% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2022-08-31 |
4 |
B |
$0.62 |
$1,856 |
I/I |
3,000 |
92,369 |
1.91 |
213% |
|
| Williams Laura A |
Chief Medical Officer |
• – – |
2022-08-31 |
4 |
B |
$0.62 |
$1,856 |
D/D |
3,000 |
245,441 |
2.66 |
213% |
|
| Blanks Robert |
See Remarks |
• – – |
2022-08-26 |
4 |
AS |
$1.04 |
$22,713 |
D/D |
(21,842) |
295,827 |
|
169% |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2022-08-22 |
4 |
S |
$0.98 |
$1,474 |
D/D |
(1,498) |
260,549 |
|
-168% |
|
538 Records found
|
|
Page 4 of 22 |
|
|
0.29 (3.6%) 
